Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q3 EPS of ($0.68), $0.12 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $305 thousand versus the consensus estimate of $300 thousand.

Financial Guidance

Today the Company provided operating expense guidance for the fourth quarter and full year 2017. For the fourth quarter and full year 2017, research and development expenses are expected to be $15 to $18 million and $47 to $50 million, respectively, and total operating expenses are expected to be $19 to $22 million and $63 to $66 million, respectively. Research and development expenses for the fourth quarter includes $5.0 million paid to Allergan in connection with the Menin-MLL license. This expense will be offset on a cash basis with a $5.0 million development milestone earned in the fourth quarter under our agreement with KHK.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.